Trial Profile
A Double-blind, Placebo-controlled, Parallel-group Study of the Effect of 5, 10 and 25 mg Daily of YF476 for 14 Days on 24-hour Ambulatory Gastric pH and Plasma Gastrin Concentrations in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Netazepide (Primary)
- Indications Reflux oesophagitis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Trio Medicines
- 17 Apr 2015 New trial record